KR101938933B1 - Compositions for alleviating, preventing or treating inflammatory Pain comprising extract from Chaenomeles sinensis and Glycyrrhizae and Aralia elata - Google Patents
Compositions for alleviating, preventing or treating inflammatory Pain comprising extract from Chaenomeles sinensis and Glycyrrhizae and Aralia elata Download PDFInfo
- Publication number
- KR101938933B1 KR101938933B1 KR1020160021067A KR20160021067A KR101938933B1 KR 101938933 B1 KR101938933 B1 KR 101938933B1 KR 1020160021067 A KR1020160021067 A KR 1020160021067A KR 20160021067 A KR20160021067 A KR 20160021067A KR 101938933 B1 KR101938933 B1 KR 101938933B1
- Authority
- KR
- South Korea
- Prior art keywords
- pain
- present
- extract
- alleviating
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 206010065390 Inflammatory pain Diseases 0.000 title claims description 13
- 241001632409 Aralia elata Species 0.000 title claims description 5
- 235000015888 Aralia elata Nutrition 0.000 title claims description 5
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 title claims description 5
- 241001507760 Chaenomeles sinensis Species 0.000 title 1
- 208000002193 Pain Diseases 0.000 claims abstract description 109
- 230000036407 pain Effects 0.000 claims abstract description 105
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 16
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 16
- 229940010454 licorice Drugs 0.000 claims abstract description 16
- 235000013305 food Nutrition 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 13
- 240000004670 Glycyrrhiza echinata Species 0.000 claims description 12
- 208000004296 neuralgia Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000021722 neuropathic pain Diseases 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 208000003251 Pruritus Diseases 0.000 claims description 9
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 208000009935 visceral pain Diseases 0.000 claims description 6
- 230000007803 itching Effects 0.000 claims description 5
- 206010058019 Cancer Pain Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 244000251905 Pseudocydonia sinensis Species 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims 2
- 235000001258 Cinchona calisaya Nutrition 0.000 claims 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 1
- 229960000948 quinine Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 238000010253 intravenous injection Methods 0.000 abstract description 4
- 244000018633 Prunus armeniaca Species 0.000 abstract description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 abstract description 2
- 241000202807 Glycyrrhiza Species 0.000 abstract 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 16
- 230000004054 inflammatory process Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229960005181 morphine Drugs 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000208340 Araliaceae Species 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 235000017788 Cydonia oblonga Nutrition 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000234280 Liliaceae Species 0.000 description 4
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 240000003768 Solanum lycopersicum Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000000929 nociceptor Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 244000024251 Aralia cordata Species 0.000 description 2
- 235000014722 Aralia cordata Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000227653 Lycopersicon Species 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000009191 jumping Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 108091008700 nociceptors Proteins 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- SQCZQTSHSZLZIQ-UHFFFAOYSA-N 1-chloropentane Chemical compound CCCCCCl SQCZQTSHSZLZIQ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical group CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000722818 Aralia Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000025962 Crush injury Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 235000002262 Lycopersicon Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241001098054 Pollachius pollachius Species 0.000 description 1
- 206010065016 Post-traumatic pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000000399 Procedural Pain Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000026216 Thoracic disease Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 235000019647 acidic taste Nutrition 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000003766 afferent neuron Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- -1 fluoroalkane Chemical compound 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- RZSCFTDHFNHMOR-UHFFFAOYSA-N n-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]pyridine-3-carboxamide;1,1-dimethyl-3-(4-propan-2-ylphenyl)urea Chemical compound CC(C)C1=CC=C(NC(=O)N(C)C)C=C1.FC1=CC(F)=CC=C1NC(=O)C1=CC=CN=C1OC1=CC=CC(C(F)(F)F)=C1 RZSCFTDHFNHMOR-UHFFFAOYSA-N 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000005223 peripheral sensory neuron Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940020463 prialt Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019997 soju Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940072651 tylenol Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a composition for alleviating, preventing or treating pain comprising a mixed extract of licorice, licorice and apricot as an active ingredient. The mixed extract of the present invention not only mitigates and treats the pain generated, but also exhibits an effect of preventing pain when administered to a subject before the pain occurs. In addition, the composition of the present invention exhibits remarkable pain relieving effect not only by intravenous injection or skin application but also by oral administration, and the composition of the present invention having such characteristics is highly applicable to foods.
Description
The present invention relates to a composition for alleviating, preventing or treating pain comprising a mixed extract of licorice, licorice and apricot as an active ingredient.
Currently, analgesics for pain are mainly anti-inflammatory drugs such as aspirin and tylenol, and most of the morphine drugs are used for severe pain. Javelin Pharmaceuticals, a specialist in pain medicine, is developing a new pain-relieving drug. The root of the analgesic effect equivalent to intravenous morphine for treating pain after severe surgery is the nasal intramuscular morphine spray Rylomine was developed. In addition, the first painkiller "Prialt" developed by Elan, an Irish pharmaceutical company, was launched in the UK.
On the other hand, the inflammatory process is a series of complicated biochemical and cellular events that are activated in response to the presence of foreign substances or tissue damage, causing swelling and pain. The inflammation process is a defense mechanism against foreign pathogenic factors, but it can cause pain even when there is no stimulation of toxic substances. The local inflammatory response releases proinflammatory cytokinins and upregulates cyclooxygenase-2 to synthesize prostaglandins, sensitizing primary afferent neurons and causing peripheral nerve cells To activate neuroimmunity. Thus, ultimately, thermal or mechanical hypersensitivity occurs. When such an inflammatory reaction occurs, it is accompanied by inflammation, which is referred to as inflammatory pain among types of pain.
Inflammatory pain, as well as the aging society, the number of patients with degenerative arthritis and back pain-related diseases is increasing every year. However, existing opioid drugs such as morphine have limited use due to drug action in the general public. . In addition, there is a great demand for the development of analgesics for pain that does not respond to existing analgesic drugs, and because of the narcotic and serious side effects of conventional opioids, which are known to have a relatively high analgesic effect, It is necessary to develop natural resources that have no side effects and have analgesic effect.
The present inventors have made extensive efforts to develop a safe material for humans, particularly a plant-derived material, which can relieve pain effectively, and as a result, it has been found that a mixed extract of Quercus, Licorice and Araliaceae is very effective for alleviating, The present invention has been completed.
Accordingly, an object of the present invention is to provide a composition for alleviating, preventing or treating pain.
Another object of the present invention is to provide a food composition and a pharmaceutical composition for alleviating, preventing or treating pain.
Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention and claims.
According to one aspect of the invention there is provided quince (Chaenomeles Sinensis , Glycyrrhizae and Aralia The present invention provides a composition for alleviating, preventing, or treating pain and inflammation, which comprises a mixed extract of a compound of formula
Hereinafter, the present invention will be described in detail.
Compositions of the present invention include pharmaceutical compositions and food compositions.
The mixed extract of the present invention not only mitigates and treats the pain generated, but also exhibits an effect of preventing pain when administered to a subject before the pain occurs. It also has an anti-inflammatory effect. The composition of the present invention exhibits remarkable pain relieving effect not only by intravenous injection or skin application but also by oral administration, and the composition of the present invention having such characteristics is highly applicable to foods.
First, the term " quince " in the specification of the present application is a fruit of a quince tree and is elliptical or ball-shaped. Promotes the secretion of ginseng digestive enzymes to improve the digestive function, make tea or soak in alcohol. At first it is green, but when it is ripe, it becomes yellowish and uneven. The fragrance is excellent, but the taste is tender and the skin is hard and it is hard to eat it. It has an essential oil ingredient on the surface and it is sticky, which adds flavor and efficacy. It is presumed that it originated in China before the Joseon Dynasty in Korea. Jeollanamdo, Chungcheongnam-do and Gyeonggi-do, and it is distributed in China and Japan. Alkaline foods contain sugars (fructose), calcium, potassium, iron, and vitamin C, tannin and tannin, and acidity such as malic acid and citric acid. It promotes the secretion of digestive enzymes and improves the digestive function, so when you are sick or diarrhea, you will feel comfortable. It is good for the metabolism to release the hangover, and to remove the phlegm, it is used as medicine for cold, bronchitis, pneumonia in one place. Thoracic disease is also effective, but the amount of urine is reduced, so be careful. When making a tea, slice it thinly 2mm thick, and then boil it with 1 side of ginger, boil it lightly, put it in honey or sugar, and put it in hot water. The liquor is sliced thinly, poured soju, and made with sugar. In addition, boiled well, soaked in honey, safflower, boiled and mashed, then put honey and water to cook and make the process of moo.
The term " licorice " in the present specification is one of the plants belonging to the rosewood and soybean family. "Licorice" has been reported to inhibit learning ability loss, but no other function has been reported.
The term "Araliaceae" in this specification is distributed in Korea, Japan, China, etc. Aralia elata (Araliaceae) belongs to Araliaceae. In May-June, sprouts are popular foods in Korea have. Aralia cordata grows from the ground to the stem, whereas Aralia cordata grows out from the tree, and from the tree, it is called the herb or tree. Anti-diabetic, anti-inflammatory, analgesic, antioxidant and anti-cancer effects are also known. The kidneys act as gangjeong, especially in the absence of adverse effects in diabetes is said to produce excellent. It is said to be good for neuralgia and hypertension in the one branch. It also stabilizes the nerve not only in early cold, neuralgia, arthritis, but also relieves anxiety, irritation and depression, and unique flavor and bitter taste improves appetite. It is said that it is good for diabetes, kidney disease and gastrointestinal disease because it contains many proteins and contains fat, carbohydrate, fiber, phosphorus, calcium, iron, vitamins (B1, B2, C) and saponin to lower blood sugar and lower blood lipid.
In the present invention, it is possible to use the mixture of the extracts of Liliaceae, Liliaceae, Lycopersicon esculentum and Lycopersicum, and then extract the mixture, or extracts of Lycopersicon esculentum, Lycopersicon esculentum and Lycopersicon esculenta with ethanol. Preferably, each herbal or herbal medicine extract is used at a weight ratio of 0.5: 2: 0.5 to 2: 0.5 to 2, preferably at a weight ratio of 1: 1: 1.
Various extracting solvents can be used when the extract of Liliaceae, Liliaceae and licorice used in the composition of the present invention is obtained by treating an extractive solvent. According to the present invention, a polar solvent or a non-polar solvent can be used. Suitable polar solvents are (i) water, (ii) alcohols (preferably methanol, ethanol, propanol, butanol, n-propanol, iso-propanol, n-butanol, 1-pentanol, Or ethylene glycol), (iii) acetic acid, (iv) DMFO (dimethylformamide) and (v) dimethyl sulfoxide (DMSO). Suitable nonpolar solvents are acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1- But are not limited to, pentane, 1-chlorobutane, 1-chloropentane, o-xylene, diisopropyl ether, 2- chloropropane, toluene, 1- chloropropane, chlorobenzene, benzene, diethyl ether, diethylsulfide, Methane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride, and THF.
According to one embodiment of the invention, the extraction solvent used in the present invention comprises (a) water, (b) an anhydrous or a lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, etc.) (D) acetone, (e) ethyl acetate, (f) chloroform, (g) butyl acetate, (h) 1,3-butylene glycol, (i) hexane and Ethyl ether. In another embodiment of the present invention, the extract of the present invention is obtained by treating water, ethanol or a combination thereof with quinquinone, lupine and licorice. According to a specific embodiment of the present invention, the extract of the present invention is obtained by treating 60 to 80% by volume of grain alcohol in corn, ginseng and licorice.
The extract used in the present invention can be prepared in a powder state by an additional process such as vacuum distillation and freeze-drying or spray drying.
As used herein, the term " extract " means that it is used in the art as a crude extract as described above, but broadly includes fractions obtained by further fractionating the extract. That is, the extract includes not only those obtained by using the above-mentioned extraction solvent but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the above extract through an ultrafiltration membrane having a constant molecular weight cut-off value, and a separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) The fraction obtained by the purification method is also included in the extract of the present invention.
As used herein, the term " comprising as an active ingredient " is meant to include an amount sufficient to achieve efficacy or activity of the following mixed extracts. Since the composition of the present invention includes extracts obtained from natural plant materials such as moths, licorice, and moths, there is no adverse effect on human body even when administered in an excessive amount. Therefore, the quantitative upper limit of the composition of the present invention contained in the composition of the present invention is And can be selected within the range.
The term " pain " is used in the present invention in its broadest sense and includes acute and chronic pain such as pain ache and pain, such as somatic pain and visceral pain; Pain, pain, inflammatory pain, dysfunctional pain, idiopathic pain, superficial pain, deep pain, itching, neuropathic pain such as centrally generated pain and peripherally generated pain, migraine, and cancer pain.
According to one embodiment of the present invention, the composition of the present invention exhibits relief, prevention or therapeutic effects against inflammatory pain.
The term " nociceptive pain " is used to include all pain caused by noxious stimuli that may or may damage nervous tissues and may include ben, cut, bruise, fracture, bone pain, bone fracture, crush injury, burn, and similar wounds. Pain receptors for tissue damage (nociceptors) are mostly located in the skin, musculoskeletal or internal organs. The term " somatic pain " is used to indicate pain that occurs in bones, joints, muscles, skin or connective tissue. This type of pain is typically very localized.
The term " visceral pain " is used herein to refer to any or all of the organs such as respiratory, gastrointestinal tract and pancreas, urinary tract and reproductive organs, Used to indicate pain that occurs. Embolic pain includes pain induced by tumor involvement of the organ capsule. Other types of visceral pain are typically caused by occlusion of the hollow viscus, characterized by intermittent cramping and severe local pain. Embolic pain may be associated with inflammation, as in the case of cystitis or reflux esophagitis.
The term " inflammatory pain " includes pain associated with active inflammation, which may be caused by trauma, surgery, infection, and autoimmune diseases.
The term " superficial pain " refers to the pain sensed by the skin segments of the nerves of the dorsal root, and is a direct pain to feel the pain at the point of stimulation.
The term " deep pain " refers to pain originating from deep organs, which varies in character and degree depending on the nature of the tissue. Particularly sensitive areas of pain are tendons, pericardium, ligaments, joints, periosteum, blood vessels and nerves. In general, deep pain is dull, spreads around, and feels wide. Pain in the deep or intestine is complicated in its mechanism, making it difficult to locate the pain rather than the surface pain, and problems such as nausea, sweating, and elevated blood pressure also appear.
The term " neuropathic pain " is used herein to denote pain resulting from sensory input of abnormal processing by the peripheral or central nervous system resulting from disturbance of the peripheral or central nervous system.
The term " procedural pain " refers to pain that occurs in internal medicine, dentistry, or surgery, and the procedure is usually scheduled or associated with acute trauma.
The term " itch " is used herein in its broadest sense and refers to all types of itchy, stinging sensations of acute intermittency and persistence that can be generally described by limiting to local. The itch may be due to idiopathic, allergic, metabolic, infectious, drug-induced, liver, kidney disease or by cancer. "Pruritus" is severe itching.
&Quot; Patient " means any animal. In one embodiment of the invention, the patient is a human. Other animals that may be treated using the composition of the invention include non-human primates (e.g., monkeys, gorillas, chimpanzees), livestock (e.g., horses, pigs, goats, rabbits, sheep, cows, llamas) But are not limited to, animals (such as guinea pigs, rats, mice, lizards, snakes, dogs, cats, ornamental fish, hamsters and birds).
Neuropathic, inflammatory, and nociceptive pain are different in etiology, pathophysiology, diagnosis and treatment. Acupuncture pain occurs in response to activation of nociceptors by a specific subset of peripheral sensory neurons, that is, intense or harmful stimuli. Acute water-soluble pain is a generally sensitive, self-limiting, and provides a biological function of protection by acting as a warning of potential or ongoing tissue damage. Pain Acceptable pain is typically very limited to locality. Examples of painful painful pain include, but are not limited to, traumatic or surgical pain, labor pain, sprains, bone fractures, burns, bumps, but are not limited to, bruises, injections, dental procedures, skin biopsies and obstructions.
Inflammatory pain is associated with joints such as postoperative, post-traumatic pain, arthritis (rheumatoid or osteoarthritis) pain, and axial low back pain. ), Pain associated with damage to muscles and tendons, or pain when there is a tissue injury or inflammation.
Pain In contrast to water-soluble pain, neuropathic pain is depicted as actual "burning," "electric," "tingling," or "shooting" do. Neuropathic pain is often defined as chronic allodynia (defined as pain due to stimuli that do not cause a normal pain response, such as a mild touch) and hyperalgesia (a high susceptibility to normal pain stimuli ) And may last for months or years after apparent healing of any damaged tissue. The composition of the present invention may be provided as a pharmaceutical composition.
When the composition of the present invention is prepared from a pharmaceutical composition, it includes not only the mixed extract of the present invention as an active ingredient, but also a pharmaceutically acceptable carrier. The pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the present invention and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).
The pharmaceutical composition of the present invention can be administered orally or parenterally. In the case of parenteral administration, the composition can be administered by intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, transdermal administration, or the like.
The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate and responsiveness of the patient, Usually, a skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001 to 100 mg / kg.
The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
According to another aspect of the present invention, there is provided a food composition for alleviating or ameliorating pain comprising as an active ingredient, a mixed extract of licorice, licorice and arthropod.
According to one embodiment of the invention, the pain relieved or prevented by the food composition of the present invention is selected from the group consisting of somatic pain, visceral pain, inflammatory pain, dysfunctional pain, idiopathic pain, Pain, superficial pain, deep pain, itching, migraine or cancer pain.
According to another embodiment of the present invention, the pain relieved or prevented by the food composition of the present invention is neuropathic pain.
When the composition of the present invention is prepared as a food composition, it contains not only the mixed extract of the present invention as an active ingredient, but also components which are ordinarily added at the time of food production. Examples thereof include protein, carbohydrate, fat, And flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be used as flavorings.
For example, when the food composition of the present invention is prepared as a drink, it may further contain citric acid, a liquid and sugar, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, .
The mixed extract of the present invention has an anti-inflammatory effect, mitigates and treats the generated pain, and has an effect of preventing pain when administered to a subject before the pain occurs. In addition, the composition of the present invention exhibits remarkable pain relieving effect not only by intravenous injection or skin application but also by oral administration, and the composition of the present invention having such characteristics is highly applicable to foods.
FIG. 1 shows the results of confirming the pain relieving effect of the mixed extract of the present invention using an acetic acid-induced writhing test.
FIG. 2 shows the results of confirming the pain relieving effect of the mixed extract of the present invention by using a hot-plate test.
FIG. 3 shows the results of confirming the pain relieving effect of the mixed extract of the present invention using a formalin test.
FIG. 4 shows the results of confirming the inflammatory pain relieving effect of the mixed extract of the present invention using formalin-induced edema.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
[ Example 1] Bonn Preparation of a mixed extract of quinces, licorice, and beetles of the invention.
In order to prepare the extract of the present invention, Chaenomeles sinensis fruit and Glycyrrhizae root were purchased from pharmacies located in Daegu, and Aralia elata ) were collected from Kyeryong Mountain (Daejeon, Republic of Korea), dried and used. After mixing 200 g of each of the above three materials, the mixture was extracted three times with 3 L of ethanol for 24 hours at room temperature, followed by filtration. The filtrate was concentrated under reduced pressure using a rotary evaporator to obtain 59 g of an ethanol extract, which was stored at room temperature.
[ Example 2] Bonn Identification of pain relief, prevention or therapeutic effect of the extract of the invention
1. Acetic acid-induced writhing test to determine pain response
Five-week-old male ICR mice were obtained from Samtako Inc (Gyeonggi-do, Korea) and were housed in a room at a relative humidity of 55 ± 5%, 22 ± 2 ° C and 12 hours day / night. Thereafter, acetic acid induction kinking experiment was carried out using the mouse as described in Koster et al (1959). After 20 minutes of administration of the extracts prepared in Example 1 (25, 50 and 100 mg / kg), ibuprofen (100 mg / kg) or morphine (5 mg / kg) to the mice, 0.8% acetic acid was administered intraperitoneally . Mice receiving each of the above substances were individually placed in a plastic observation chamber and the number of times that each mouse stretched the hind leg and stretched the abdomen at 10 to 40 minutes after acetic acid administration was calculated. The results are shown in Fig.
As shown in FIG. 1, in the group administered with 50 or 100 mg / kg of the ethanol extract of the present invention, it was confirmed that the pain response was significantly reduced (56.9 ± 5.5 and 61.0 ± 12.8) as compared with the control group.
2. Hot - Confirmation of pain response by hot-plate test
The hot-plate experiment was carried out according to the already known method (Woolfe and Mcdonald, 1944). The mouse was placed in a hot-plate (IITC) maintained at 55 ± 0.5 ° C and covered with a Plexiglas wall cylinder. The basal hot-plate latency time was set to 5 seconds or less. Respectively. (25, 50 and 100 mg / kg), ibuprofen (100 mg / kg) or morphine (5 mg / kg) prepared in Example 1 were administered to each mouse. After 15, 30, 45, 60 and 90 minutes of substance administration, the degree of jumping from the mouse hot-plate surface was measured and if no jumping behavior was observed for 20 seconds observed, Hot-play. The results are shown in Fig.
As shown in FIG. 2, when the ethanol extract of the present invention was administered at 25, 50 and 100 mg / kg, the pain response was not inhibited together with the ibuprofen-treated group, and only the morphine-treated group significantly decreased the pain response .
3. Formalin The formalin test Identify pain response
The formalin test was performed according to the known method (Hunskaar et al., 1985). After 1 hour of administration of the extract (25, 50 and 100 mg / kg), ibuprofen (100 mg / kg) or morphine (5 mg / kg) prepared in Example 1 to the mouse, 20 μl of saline containing 2% After injection on the surface, the mice were placed in an acrylic box, and then the tail of formalin was observed for 30 minutes. After injecting formalin, the licking time was measured for 0 to 5 minutes and the pain response was measured for 20 to 30 minutes after the injection of formalin, which is the time when the inflammation reaction is induced. The results are shown in Fig.
As shown in FIG. 3, in the group administered with 25, 50 and 100 mg / kg of the ethanol extract of the present invention, the pain of the secondary inflammatory reaction period (20 to 30 minutes after the formalin administration) as compared with the control group (99.0 ± 8.9 s) (57.4 ± 9.4, 52.5 ± 8.0, and 44.6 ± 10.9 s, respectively), respectively.
4. Formalin Induced Edema size Confirmed inflammatory response
After injecting formalin in the same manner as in Example 2.3, mice were excised and the volume of the edema was measured. The vertical thickness of edema from the metatarsal of the group injected with formalin before or 18 hours after injection of formalin was measured using a fine caliper (Vernier caliper 530 series, Mitutoyo, Japan). The thickness was calculated by subtracting the thickness before administration from the thickness after administration of formalin and expressed in mm. The results are shown in Fig.
As shown in FIG. 4, when the ethanol extract of the present invention was administered to mice at 50 and 100 mg / kg, it was confirmed that the thickness of the rear flank of the mice ((0.72 ± 0.03 mm) . Thus, it was confirmed that the extract of the present invention can reduce inflammatory edema.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160021067A KR101938933B1 (en) | 2016-02-23 | 2016-02-23 | Compositions for alleviating, preventing or treating inflammatory Pain comprising extract from Chaenomeles sinensis and Glycyrrhizae and Aralia elata |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160021067A KR101938933B1 (en) | 2016-02-23 | 2016-02-23 | Compositions for alleviating, preventing or treating inflammatory Pain comprising extract from Chaenomeles sinensis and Glycyrrhizae and Aralia elata |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170099105A KR20170099105A (en) | 2017-08-31 |
| KR101938933B1 true KR101938933B1 (en) | 2019-01-15 |
Family
ID=59760965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160021067A KR101938933B1 (en) | 2016-02-23 | 2016-02-23 | Compositions for alleviating, preventing or treating inflammatory Pain comprising extract from Chaenomeles sinensis and Glycyrrhizae and Aralia elata |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101938933B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230139176A (en) | 2022-03-25 | 2023-10-05 | (주)휴벳 | Composition for preventing or treating of inflammatory disease comprising extract of aralia elata and cirsium japonicum |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190126565A (en) | 2018-05-02 | 2019-11-12 | 김진희 | A composition for improving, preventing and treating of pain containing oriental medicine herbs oil extract as an active ingredient |
-
2016
- 2016-02-23 KR KR1020160021067A patent/KR101938933B1/en active IP Right Grant
Non-Patent Citations (3)
| Title |
|---|
| Environmental Toxicology and Pharmacology, Vol. 28, pp. 333-341 (2009)* |
| Korean Journal of Acupuncture. Vol. 28, No. 4, pp.49-58 (2011)* |
| The Journal of Oriental Obsterics & Gynecology, Vol. 21, No. 4, pp. 36-48 (2008)* |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230139176A (en) | 2022-03-25 | 2023-10-05 | (주)휴벳 | Composition for preventing or treating of inflammatory disease comprising extract of aralia elata and cirsium japonicum |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170099105A (en) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mazumder et al. | Phyto-pharmacology of Berberis aristata DC: a review | |
| Singh et al. | Traditional uses, phytochemistry and pharmacological properties of Capparis decidua: An overview | |
| KR20100042337A (en) | The composition of traditional oriental medicines for reheumatoid arthritis and the method of preparing medicine for it | |
| KR101716763B1 (en) | Breeding Method for Crickets Comprising Ginsenoside Type Saponin and Polysaccharide from Panax ginseng and their Extracts and Food Composition | |
| RU2668135C1 (en) | Pharmaceutical composition for the treatment and prevention of degenerative neurological disorders which comprises, as an active ingredient, a mixed root extract of the tree peony root, the root of dahuric angelica and the root of thorowax or its fraction | |
| JP6539780B2 (en) | A composition for preventing or treating arthritis, which comprises an extract of Usbanokogiri moku as an active ingredient | |
| KR101938933B1 (en) | Compositions for alleviating, preventing or treating inflammatory Pain comprising extract from Chaenomeles sinensis and Glycyrrhizae and Aralia elata | |
| KR101584279B1 (en) | Compositions for Alleviating, Preventing or Treating Pain Comprising Ecklonia cava Extracts as Active Ingredients | |
| KR101500485B1 (en) | Compositions for Alleviating, Preventing or Treating Pain Comprising Ilex paraguayensis Extracts as Active Ingredients | |
| KR101680840B1 (en) | Compositions for Alleviating, Preventing or Treating Pain Comprising Cnidium officinale Makino Extracts as Active Ingredients | |
| KR101784591B1 (en) | Compositions for alleviating, preventing or treating inflammatory Pain comprising extract from Vitis amurensis, Glycyrrhizae and Aralia cordata | |
| KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
| KR101598600B1 (en) | Compositions for Alleviating, Preventing or Treating Pain Comprising Harapagophytum procumbens and Acanthopanax senticosus Extracts as Active Ingredients | |
| KR102106325B1 (en) | Compositions for Alleviating, Preventing or Treating Pain Comprising Camellia japonica L. Extracts | |
| Sangeetha et al. | A Review on traditional herb Portulaca oleracea | |
| KR102234860B1 (en) | Composition for prevention and treatment of muscle atrophy comprising lespedeza bicolor extract | |
| Kumar et al. | The Pharmacological activities of mother of thousand (Kalanchoe pinnata) | |
| KR20210106130A (en) | Composition for prevention and alleviation of inflammation and neuropathic pain | |
| Sari et al. | Overview of traditional use, phytochemical and pharmacological activities of cucumber (Cucumis sativus L.) | |
| CN106163535B (en) | Antiobesity agent comprising walnut extract | |
| KR101607545B1 (en) | Composition for preventing, improving or treating of arthritis comprising herbal extract mixture as effective component | |
| KR20130129616A (en) | Composition comprising aged honey, mulberry and eucommiae cortex for preventing or treatment of arthritis | |
| KR102277061B1 (en) | Pharmaceutical composition for prevention or treatment of muscular disease comprising Codonopsis lanceolata extract as an active ingredient | |
| Bisong et al. | Effects of Aqueous Leaf Extracts of Murraya koenigii on Learning and Memory in Mice | |
| KR101934811B1 (en) | Preparation for improving blood circulation comprising mixed medicinal extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |